• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MMP-2 强阳性和 TIMP-2 弱阳性免疫染色组合是子宫内膜癌的一个重要预后因素。

Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.

出版信息

Dis Markers. 2013;35(4):261-6. doi: 10.1155/2013/416870.

DOI:10.1155/2013/416870
PMID:24344400
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3810671/
Abstract

OBJECTIVE

The aim of this study was to evaluate the combined effects of MMP-2 and TIMP-2 protein immunoreactivities on the prognosis in endometrial carcinoma.

METHODS

Paraffin-embedded tissue samples from 225 primary endometrioid adenocarcinomas and 13 histologies other than endometrioid adenocarcinoma were immunohistochemically stained for MMP-2 and TIMP-2.

RESULTS

In Kaplan-Meier analysis, the 5-year cancer-specific survival rate of the endometrioid adenocarcinoma patients with negative MMP-2 and positive TIMP-2 staining was 100%, whereas only 78% of patients presenting with positive MMP-2 and negative TIMP-2 staining results were alive at that time. In Cox regression analysis, patients with positive MMP-2 and negative TIMP-2 immunostaining had a 4.7-fold relative risk of death from endometrial carcinoma compared to the group of patients with negative MMP-2 and positive or negative TIMP-2 immunoreaction.

CONCLUSIONS

MMP-2 seems to be the main metalloproteinase determining the prognosis in endometrial carcinoma. Combination of strong MMP-2 and weak TIMP-2 immunostainings was the most potent prognostic marker for poor survival.

摘要

目的

本研究旨在评估 MMP-2 和 TIMP-2 蛋白免疫活性对子宫内膜癌预后的综合影响。

方法

对 225 例原发性子宫内膜样腺癌和 13 例非子宫内膜样腺癌的石蜡包埋组织样本进行 MMP-2 和 TIMP-2 的免疫组织化学染色。

结果

在 Kaplan-Meier 分析中，MMP-2 阴性和 TIMP-2 阳性染色的子宫内膜样腺癌患者的 5 年癌症特异性生存率为 100%，而 MMP-2 阳性和 TIMP-2 阴性染色结果的患者中只有 78%存活。在 Cox 回归分析中，与 MMP-2 阴性和 TIMP-2 阳性或阴性免疫反应组相比，MMP-2 阳性和 TIMP-2 阴性免疫染色的患者死于子宫内膜癌的相对风险为 4.7 倍。

结论

MMP-2 似乎是决定子宫内膜癌预后的主要金属蛋白酶。强 MMP-2 和弱 TIMP-2 免疫染色的组合是生存不良的最强预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1271/3810671/538ebab0dd30/DM35-04-416870.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1271/3810671/d56dc8273f64/DM35-04-416870.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1271/3810671/bd405f1bf27b/DM35-04-416870.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1271/3810671/538ebab0dd30/DM35-04-416870.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1271/3810671/d56dc8273f64/DM35-04-416870.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1271/3810671/bd405f1bf27b/DM35-04-416870.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1271/3810671/538ebab0dd30/DM35-04-416870.003.jpg

相似文献

1
Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.MMP-2 强阳性和 TIMP-2 弱阳性免疫染色组合是子宫内膜癌的一个重要预后因素。
Dis Markers. 2013;35(4):261-6. doi: 10.1155/2013/416870.
2
Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions.子宫内膜肿瘤侵袭性与金属蛋白酶2及金属蛋白酶组织抑制剂2的表达有关。
Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1911-7. doi: 10.1111/j.1525-1438.2006.00717.x.
3
Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.基质金属蛋白酶组织抑制因子-2的免疫反应性与子宫内膜癌的良好预后相关。
Tumour Biol. 2012 Aug;33(4):935-41. doi: 10.1007/s13277-012-0321-7. Epub 2012 Jan 21.
4
Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.宫颈癌患者生存中 MMP-2、MMP-9、MMP-14、TIMP-1、TIMP-2 和 VEGF-A 的肿瘤和基质表达：竞争风险分析。
BMC Cancer. 2020 Jul 15;20(1):660. doi: 10.1186/s12885-020-07150-3.
5
[Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].[基质金属蛋白酶及其组织抑制剂在肝细胞癌中的表达]
Hunan Yi Ke Da Xue Xue Bao. 2003 Jun;28(3):212-6.
6
[Activity of matrix metalloproteinases -2 and -9 (MMP-2 and MMP-9) and content of their tissue inhibitors in endometrial cancer--a preliminary study].基质金属蛋白酶-2和-9（MMP-2和MMP-9）活性及其组织抑制剂在子宫内膜癌中的含量——一项初步研究
Ginekol Pol. 2007 May;78(5):366-72.
7
Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.浆液性积液中的卵巢癌细胞显示MMP-2和TIMP-2 mRNA水平改变。
Eur J Cancer. 2001 Nov;37(16):2040-9. doi: 10.1016/s0959-8049(01)00235-0.
8
Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.基质金属蛋白酶-2 及其组织抑制剂-2 在胎儿和肿瘤性甲状腺组织中的表达及其作为乳头状癌诊断和预后标志物的意义。
Cancer Biomark. 2011;11(1):49-58. doi: 10.3233/CBM-2012-0258.
9
Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study.金属蛋白酶-2、-7和-9以及金属蛋白酶组织抑制剂-1和-2在正常、增生性和肿瘤性子宫内膜中的表达：一项临床病理相关性研究。
Ann Oncol. 2006 Apr;17(4):637-45. doi: 10.1093/annonc/mdj129. Epub 2006 Jan 11.
10
Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer.基质金属蛋白酶-2及其特异性抑制剂金属蛋白酶组织抑制因子-2在胃癌中的临床病理意义
Histol Histopathol. 2008 Aug;23(8):917-23. doi: 10.14670/HH-23.917.

引用本文的文献

1
Soluble guanylyl cyclase beta1 subunit targets epithelial-to-mesenchymal transition and downregulates Akt pathway in human endometrial and cervical cancer cells.可溶性鸟苷酸环化酶β1亚基靶向人子宫内膜癌和子宫颈癌细胞的上皮-间质转化并下调Akt信号通路。
Heliyon. 2023 Dec 19;10(1):e23927. doi: 10.1016/j.heliyon.2023.e23927. eCollection 2024 Jan 15.
2
Clinical and prognostic features of MMP-2 and VEGF in AEG patients.AEG患者中MMP-2和VEGF的临床及预后特征
Open Med (Wars). 2021 May 14;16(1):786-794. doi: 10.1515/med-2021-0252. eCollection 2021.
3
Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.

本文引用的文献

1
Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.基质金属蛋白酶组织抑制因子-2的免疫反应性与子宫内膜癌的良好预后相关。
Tumour Biol. 2012 Aug;33(4):935-41. doi: 10.1007/s13277-012-0321-7. Epub 2012 Jan 21.
2
Genetic patterns of metalloproteinases and their tissular inhibitors - clinicopathologic and prognostic significance in colorectal cancer.金属蛋白酶及其组织抑制剂的基因模式——在结直肠癌中的临床病理及预后意义
Rom J Morphol Embryol. 2011;52(1 Suppl):231-6.
3
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.
宫颈癌患者生存中 MMP-2、MMP-9、MMP-14、TIMP-1、TIMP-2 和 VEGF-A 的肿瘤和基质表达：竞争风险分析。
BMC Cancer. 2020 Jul 15;20(1):660. doi: 10.1186/s12885-020-07150-3.
4
Clinical significance of matrix metalloproteinase-2 in endometrial cancer: A systematic review and meta-analysis.基质金属蛋白酶-2在子宫内膜癌中的临床意义：一项系统评价与Meta分析
Medicine (Baltimore). 2018 Jul;97(29):e10994. doi: 10.1097/MD.0000000000010994.
5
Overexpression of the matrix metalloproteinase 11 gene is a potential biomarker for type 1 endometrial cancer.基质金属蛋白酶11基因的过表达是I型子宫内膜癌的一个潜在生物标志物。
Oncol Lett. 2018 Jul;16(1):1073-1078. doi: 10.3892/ol.2018.8714. Epub 2018 May 16.
6
The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and -9 in angiogenesis, metastasis, and prognosis of endometrial cancer.血管内皮生长因子-A以及基质金属蛋白酶-2和-9对子宫内膜癌血管生成、转移及预后的影响。
Onco Targets Ther. 2017 Sep 19;10:4617-4624. doi: 10.2147/OTT.S132558. eCollection 2017.
7
Post-transcriptional Regulation of MMP16 and TIMP2 Expression miR-382, miR-410 and miR-200b in Endometrial Cancer.子宫内膜癌中MMP16和TIMP2表达的转录后调控：miR-382、miR-410和miR-200b
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):389-401. doi: 10.21873/cgp.20049.
8
Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients.血清HE4和MMP2水平在子宫内膜癌患者中的临床意义。
Onco Targets Ther. 2017 Jun 27;10:3169-3175. doi: 10.2147/OTT.S136750. eCollection 2017.
9
Effects of RNA silencing of matrix metalloproteinase-2 on the growth of esophageal carcinoma cells .基质金属蛋白酶-2的RNA沉默对食管癌细胞生长的影响
Oncol Lett. 2017 Mar;13(3):1119-1124. doi: 10.3892/ol.2016.5542. Epub 2016 Dec 27.
10
αvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression.αvβ6整合素是转化生长因子β1介导的基质金属蛋白酶2表达所必需的。
Biochem J. 2015 Mar 15;466(3):525-36. doi: 10.1042/BJ20140698.
基质金属蛋白酶（MMPs）和金属蛋白酶组织抑制剂（TIMPs）：肿瘤细胞黏附中的正向和负向调节因子。
Semin Cancer Biol. 2010 Jun;20(3):161-8. doi: 10.1016/j.semcancer.2010.05.002. Epub 2010 May 12.
4
MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium.与低级别子宫内膜样癌和增殖期子宫内膜相比，子宫内膜浆液性癌中基质金属蛋白酶-2（MMP-2）、金属蛋白酶组织抑制因子-1（TIMP-1）、E-钙黏蛋白和β-连环蛋白的表达情况。
Acta Obstet Gynecol Scand. 2008;87(8):868-74. doi: 10.1080/00016340802253775.
5
Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer.基质金属蛋白酶-2及其特异性抑制剂金属蛋白酶组织抑制因子-2在胃癌中的临床病理意义
Histol Histopathol. 2008 Aug;23(8):917-23. doi: 10.14670/HH-23.917.
6
The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2.肿瘤微环境：金属蛋白酶组织抑制剂-2的非基质金属蛋白酶依赖性效应的调节作用
Cancer Metastasis Rev. 2008 Mar;27(1):57-66. doi: 10.1007/s10555-007-9105-8.
7
Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.基质金属蛋白酶-1、-2、-7和-13以及金属蛋白酶组织抑制剂-1、-2、-3和-4在结直肠癌中的预后意义
Int J Cancer. 2007 Aug 15;121(4):714-23. doi: 10.1002/ijc.22747.
8
The role of matrix metalloproteinases-2, -7 and -9 and beta-catenin in high grade endometrial carcinoma.基质金属蛋白酶-2、-7和-9以及β-连环蛋白在高级别子宫内膜癌中的作用。
Histopathology. 2007 Feb;50(3):348-57. doi: 10.1111/j.1365-2559.2007.02612.x.
9
Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions.子宫内膜肿瘤侵袭性与金属蛋白酶2及金属蛋白酶组织抑制剂2的表达有关。
Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1911-7. doi: 10.1111/j.1525-1438.2006.00717.x.
10
MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma.基质金属蛋白酶-2的表达与子宫内膜癌中的CA 125及临床病程相关。
Gynecol Oncol. 2007 Jan;104(1):217-21. doi: 10.1016/j.ygyno.2006.08.006. Epub 2006 Sep 22.